Viralgen receives cGMP certification to produce rAAV commercial grade product at new facility in San Sebastian, Spain

Certification expands Viralgen’s capacity threefold and positions the company as a worldleading CDMO. New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors using Pro10™, the leading cell line on the market.   Viralgen Vector Core (Viralgen), an independently operated subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio),…